Abstract
The effect of aging on cognition in cognitively healthy adult populations remains poorly investigated. Given that cognition evolves in time and thus, during aging, and becomes eroded in several disorders, some of which have recently acquired biological definitions, it is imperative to understand the process of cognitive aging. To determine the association of aging with cognitive performance in a cognitively healthy population, we studied cognitive performance in population-based cohort of 673 adults (aged 25-89). We found a gradual decline in cognitive performance across the lifespan, which requires two decades to demonstate significant change. This age-related decline was not significantly altered by either gender or education. These findings contribute to understand cognitive aging and provide essential data on physiological cognition for more precise diagnostics and timely intervention of early changes in cognition.
Competing Interest Statement
Maria Vassilaki has received research funding from Roche and Biogen in the past; she currently consults for Roche, receives research funding from NIH and EU/ St. Anne's University Hospital Brno (Czech Republic), and has equity ownership in Abbott Laboratories, Johnson and Johnson, Medtronic, and Amgen. In addition, she is currently an Associate Editor for the Journal of Alzheimer's Disease and a Guest Editor for the Frontiers Research Topic collection "Multimorbidity in the Context of Neurodegenerative Disorders" (participating journals: Frontiers in Neuroscience-Neurodegeneration and Frontiers in Aging Neuroscience). No other disclosures were reported.
Funding Statement
The study was funded by the European Regional Development Fund - Project ENOCH 750 (No. CZ.02.1.01/0.0/0.0/16_019/0000868). The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research protocols of the study were approved by the Institutional Review Board and by the ethics committee of St. Anne's University Hospital, Brno, Czech Republic. All participants of the Kardiovize study provided written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used in this study are available on request immediately following the publication to anyone who submits the online request that will be approved by the St. Anne's University Hospital International Clinical Research Centre internal board. The researches have to provide their research intentions and goals, and specify, and justify requested variables. The data will be provided for a limited and well-defined time via cloud service or e-mail in csv format. After defined period the data should be returned, and all other copies should be destroyed.
